Elequin Capital’s Gilead Sciences GILD Stock Holding History

Elequin Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,719	Closed	-$128K	–	415
2023 Q3	$128K	Buy	+1,719	New	+$132K	0.02%	133

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Elequin Capital's GILD Position: Q4 2023 in Review

Elequin Capital sold out of Gilead Sciences (GILD) in Q4 2023, closing a stake of 1,719 shares — an estimated $128K sold.

Elequin Capital first reported a position in GILD in Q3 2023 and held it in 1 quarter. The position peaked at $128K in Q3 2023. 1,776 funds tracked by Wall St. Rank hold GILD as of Q4 2023.

Elequin Capital reported no remaining Gilead Sciences position as of Q4 2023 after selling out during the quarter.
Elequin Capital sold 1,719 Gilead Sciences shares in Q4 2023, an estimated $128K.
Elequin Capital first reported a position in Gilead Sciences in Q3 2023 and held it in 1 quarter.
Elequin Capital's Gilead Sciences position peaked at $128K in Q3 2023.
1,776 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2023.

Based on Elequin Capital's 13F filing for Q4 2023, filed 14 Feb 2024.